SEC Form 4 · accession 0000939767-16-000160
EXELIXIS, INC. · EXEL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gisela Schwab
Officer — Pres Prod Dev & Med Aff & CMO
Period of report
Mar 7, 2016
Accepted (ET)
Mar 8, 2016 · 7:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000939767
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (right to buy)F2,F1 | $1.70 | Mar 7, 2016 | A | 125,000 | A | Mar 7, 2016 | Sep 18, 2021 | Common Stock | 125,000 | 125,000 | D |
| Option (right to buy)F4,F3 | $1.90 | Mar 7, 2016 | A | 62,500 | A | Mar 7, 2016 | Feb 4, 2022 | Common Stock | 62,500 | 62,500 | D |
Explanation of responses
- F1On September 19, 2014, the Reporting Person was granted a performance-based stock option to purchase 500,000 shares of common stock pursuant to the Exelixis, Inc. 2014 Equity Incentive Plan. Vesting of the option is tied to performance goals set by the Compensation Committee (the "Committee") as follows: (i) 50% of the option will vest if the Committee determines that top-line efficacy data received from the METEOR phase 3 pivotal trial of cabozantinib in metastatic renal cell carcinoma ("mRCC") met its primary endpoint at a specified level, with such result to occur no later than a specified date; (ii) 25% of the option will vest if the Committee confirms that a new drug application ("NDA") for cabozantinib for the treatment of mRCC is accepted for review by the United States Food and Drug Administration ("FDA") by a specified date; and (iii) 25% of the option will vest if the Committee confirms that the FDA has approved cabozantinib for the treatment of mRCC by a specified date.
- F2On March 7, 2016, the Committee convened to determine that the NDA for cabozantinib for the treatment of mRCC was accepted for review by the FDA within the time period permitted by the performance goals, resulting in the vesting of the option as to 125,000 shares.
- F3On February 5, 2015, the Reporting Person was granted a performance-based stock option to purchase 250,000 shares of common stock pursuant to the Exelixis, Inc. 2014 Equity Incentive Plan. Vesting of the option is tied to performance goals set by the Committee as follows: (i) 50% of the option will vest if the Committee determines that top-line efficacy data received from the METEOR phase 3 pivotal trial of cabozantinib in mRCC met its primary endpoint at a specified level, with such result to occur no later than a specified date; (ii) 25% of the option will vest if the Committee confirms that an NDA for cabozantinib for the treatment of mRCC is accepted for review by the FDA by a specified date; and (iii) 25% of the option will vest if the Committee confirms that the FDA has approved cabozantinib for the treatment of mRCC by a specified date.
- F4On March 7, 2016, the Committee convened to determine that the NDA for cabozantinib for the treatment of mRCC was accepted for review by the FDA within the time period permitted by the performance goals, resulting in the vesting of the option as to 62,500 shares.